F

Fulcrum Therapeutics
D

FULC

6.85000
USD
0.08
(1.11%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-685
حجم السوق
369,758,246
أصول ذات صلة
E
ENJ
-0.170
(-0.84%)
20.080 USD
L
LINK
0.01000
(0.18%)
5.50000 USD
S
SAND
0.12000
(1.30%)
9.35000 USD
المزيد
الأخبار المقالات

العنوان: Fulcrum Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.